Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

Hepatology Research

Volumn 29, Issue 4, 2004, Pages 216-222

  Itakura, Jun ^a   Izumi, Namiki ^a   Nishimura, Yuki ^a   Inoue, Kazunari ^a   Ueda, Ken ^a   Nakanishi, Hiroyuki ^a   Tsuchiya, Kaoru ^a   Hamano, Kosei ^a   Asahina, Yasuhiro ^a   Kurosaki, Masayuki ^a   Uchihara, Masakatsu ^a   Miyake, Shozo ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Bezafibrate; Primary biliary cirrhosis; Randomized crossover trial; UCDA

Indexed keywords

ALKALINE PHOSPHATASE; BEZAFIBRATE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN M; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LABORATORY TEST; MALE; MONOTHERAPY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 4043168579     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2004.04.001     Document Type: Article

References (25)

1. Neuberger J. Primary biliary cirrhosis Lancet 350 9081 1997 875-879
2. Leuschner U. Fischer H. Kurtz W. et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial Gastroenterology 97 5 1989 1268-1274
3. Poupon R.E. Poupon R. Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group N Engl. J. Med. 330 19 1994 1342-1347
4. Lindor K.D. Dickson E.R. Baldus W.P. et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis Gastroenterology 106 5 1994 1284-1290
5. Heathcote E.J. Cauch-Dudek K. Walker V. et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 19 5 1994 1149-1156
6. Goulis J. Leandro G. Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary: a meta-analysis Lancet 354 9184 1999 1053-1060
7. Papatheodoridis G.V. Hadziyannis E.S. Deutsch M. Hadziyannis S.J. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial Am. J. Gastroenterol. 97 8 2002 2063-2070
8. Day A.P. Feher M.D. Chopra R. Mayne P.D. The effect of bezafibrate treatment on serum alkaline phosphatase isozyme activities Metabolism 42 7 1993 839-842
9. Kanda T. Yokosuka O. Imazeki F. Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J. Gastroenterol. 38 6 2003 573-578
10. Ludwig J. New concepts in biliary cirrhosis Semin. Liver Dis. 7 4 1987 293-301
11. Iwasaki S. Tsuda K. Ueta H. et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis Hepatol. Res. 16 1 1999 12-18
12. Miyaguchi S. Ebinuma H. Imaeda H. et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 47 36 2000 1518-1521
13. Chianale J. Vollrath V. Wielandt A.M. et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse Biochem. J. 314 Pt 3 1996 781-786
14. Jacquemin E. De Vree J.M. Cresteil D. et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood Gastroenterology 120 6 2001 1448-1458
15. Ros J.E. Libbrecht L. Geuken M. Jansen P.L. Roskams T.A. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease J. Pathol. 200 5 2003 553-560
16. Devchand P.R. Keller H. Peters J.M. Vazquez M. Gonzalez F.J. Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control Nature 384 6604 1996 39-43
17. Delerive P. Fruchart J.C. Staels B. Peroxisome proliferator-activated receptors in inflammation control J. Endocrinol. 169 3 2001 453-459
18. Kumar D. Tandon R.K. Use of ursodeoxycholic acid in liver diseases J. Gastroenterol. Hepatol. 16 1 2001 3-14
19. Poupon R.E. Huet P.M. Poupon R. Bonnand A.M. Nhieu J.T. Zafrani E.S. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis Hepatology 24 5 1996 1098-1103
20. Gonzalez-Koch A. Brahm J. Antezana C. Smok G. Cumsille M.A. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone J. Hepatol. 27 1 1997 143-149
21. Leuschner M. Guldutuna S. You T. Hubner K. Bhatti S. Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis J. Hepatol. 25 1 1996 49-57
22. Wolfhagen F.H. van Hoogstraten H.J. van Buuren H.R. et al. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary chirrhosis: a 1-year randomized, placebo-controlled study J. Hepatol. 29 5 1998 736-742
23. Neuman M.G. Cameron R.G. Haber J.A. Katz G.G. Blendis L.M. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis Liver 22 3 2002 235-244
24. Angulo P. Batts K.P. Therneau T.M. Jorgensen R.A. Dickson E.R. Lindor K.D. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis Hepatology 29 3 1999 644-647
25. Poupon R.E. Bonnand A.M. Chretien Y. Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis Hepatology 29 6 1999 1668-1671